A CHECKLIST FOR SUITABILITY OF BIOMARKERS AS SURROGATE END-POINTS IN CHEMOPREVENTION OF BREAST-CANCER

被引：0

作者：

BOGOCH, S

BOGOCH, ES

机构：

[1] BOSTON UNIV, SCH MED, BOSTON, MA 02215 USA

[2] ONCOLAB, BOSTON, MA 02215 USA

来源：

JOURNAL OF CELLULAR BIOCHEMISTRY | 1994年

关键词：

ANTIMALIGNIN; CANCER ANTIBODY; CANCER ANTIGEN; CANCER VACCINE; CYTOTOXICITY; GLYCOPROTEINS; IMMUNOSURVEILLANCE; MALIGNIN;

D O I：

暂无

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

By reference to a ''checklist'' of requirements for substances or processes to qualify as surrogate endpoint biomarkers, both malignin and antimalignin antibody are found to be suitable for use in breast cancer chemoprevention trials. Antimalignin has been shown to be highly specific and sensitive, modulatable and reversible, detectable early in appearance of malignancy and upon recovery therefrom, and differentially expressed in high-risk individuals as compared with the general population. (C) 1994 Wiley-Liss, Inc.

引用

页码：173 / 185

页数：13

共 50 条

[31] SUBJECTS AND RECRUITMENT STRATEGIES FOR A SHORT-TERM PHASE-II CHEMOPREVENTION TRIAL OF BREAST-CANCER USING SURROGATE END-POINT BIOMARKERS
VOGEL, VG
JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 257 - 258
[32] Diagnosis of small sized invasive breast cancer by an Australian mammography screening service: Surrogate end-points for mortality reduction
Rickard, M
Donnellan, M
AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 1998, 68 (06): : 415 - 418
[33] HISTOLOGICAL SURROGATE END-POINTS USING QUANTITATIVE CYTOMETRY - OVERVIEW
BAAK, JPA
JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 96 - 97
[34] Optimizing the implementation of future treatment using surrogate end-points
Dowsett, Mitch
BREAST CANCER RESEARCH, 2008, 10 (Suppl 4)
[35] Surrogate end-points for treatment trials of hepatitis B virus
Griffiths, P. D.
REVIEWS IN MEDICAL VIROLOGY, 2010, 20 (04) : 199 - 201
[36] Optimizing the implementation of future treatment using surrogate end-points
Mitch Dowsett
Breast Cancer Research, 10
[37] WHICH SURROGATE END-POINTS ARE VALID FOR ASSESSING THROMBOTIC TENDENCY
FREDD, S
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1992, 56 (04): : 814 - 814
[38] WORKSHOP ON CHEMOPREVENTION OF BREAST-CANCER
MUGGIA, FM
GREENSPAN, EM
CANCER RESEARCH, 1984, 44 (07) : 3151 - 3154
[39] TAMOXIFEN CHEMOPREVENTION OF BREAST-CANCER
CUZICK, J
BAUM, M
POWLES, T
CANCER INVESTIGATION, 1986, 4 (05) : 502 - 503
[40] PROSPECTS FOR THE CHEMOPREVENTION OF BREAST-CANCER
BAUM, M
ZIV, Y
COLLETTA, A
BRITISH MEDICAL BULLETIN, 1991, 47 (02) : 493 - 503

← 1 2 3 4 5 →